ForPatients
by Roche

ObesityCardiovascular Disease

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established Cardiovascular Disease

Trial Status	Trial Runs In	Trial Identifier
Recruiting	3 Countries	NCT07843472 2026-526190-41-00 CC46446

The clinical trial information herein is sourced from public registries such as ClinicalTrials.gov, EuClinicalTrials.eu, and ISRCTN.com. Additional patient-friendly (lay) content has been prepared by Roche to support understanding.

Official Title:

A Phase III, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once Weekly Petrelintide Vs. Placebo in Participants With Overweight Or Obesity And Established Cardiovascular Disease

Trial Summary:

This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and established cardiovascular disease (CVD).

Hoffmann-La Roche	Phase 3
Sponsor	Phase

NCT07843472 2026-526190-41-00 CC46446
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	#40 Years	No

Inclusion Criteria:

- Participants with BMI # 27 kg/m² and established CVD
- History of at least one self-reported unsuccessful dietary effort to lose body weight

© 2022 F. Hoffmann-La Roche Ltd

Exclusion Criteria:

- Known history of Type 1 diabetes mellitus
- Current or previous treatment with petrelintide or any other amylin analog

© 2022 F. Hoffmann-La Roche Ltd